[1] S. M. Laville et al., “Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort.,” Br. J. Clin. Pharmacol., vol. 84, no. 12, pp. 2811–2823, Dec. 2018, doi: 10.1111/bcp.13738.
[2] W. H. Tesfaye, R. L. Castelino, B. C. Wimmer, and S. T. R. Zaidi, “Inappropriate prescribing in chronic kidney disease: A systematic review of prevalence, associated clinical outcomes and impact of interventions.,” Int. J. Clin. Pract., vol. 71, no. 7, Jul. 2017, doi: 10.1111/ijcp.12960.
[3] S. D. S. Fraser et al., “The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study,” BMC Nephrol., vol. 16, p. 193, Dec. 2015, doi: 10.1186/s12882-015-0189-z.
[4] R. Spencer, B. Bell, A. J. Avery, G. Gookey, and S. M. Campbell, “Identification of an updated set of prescribing--safety indicators for GPs.,” Br. J. Gen. Pract., vol. 64, no. 621, pp. e181-90, Apr. 2014, doi: 10.3399/bjgp14X677806.
[5] “WHO Collaborating Centre for Drug Statistics Methodology. Structure and principles. (Last updated: 2018-02-15),” 2018. [Online]. Available: https://www.whocc.no/atc/structure_and_principles/. [Accessed: 29-Jan-2020].
[6] N. R. Hill et al., “Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.,” PLoS One, vol. 11, no. 7, p. e0158765, 2016, doi: 10.1371/journal.pone.0158765.
[7] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group., “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease,” Off. J. Int. Soc. Nephrol. Kidney Int. Suppl., vol. 3, no. 1, pp. 1–150, 2013.
[8] T. D. Nolin, “A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD,” Semin. Dial., vol. 28, no. 4, pp. 325–329, 2015, doi: 10.1111/sdi.12374.
[9] U. Bilge, G. Sahin, I. Unluoglu, M. Ipek, M. Durdu, and A. Keskin, “Inappropriate use of nonsteroidal anti-inflammatory drugs and other drugs in chronic kidney disease patients without renal replacement therapy.,” Ren. Fail., vol. 35, no. 6, pp. 906–910, Jul. 2013, doi: 10.3109/0886022X.2013.801272.
[10] I. M. Schmidt et al., “Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study,” Clin. Kidney J., vol. 12, no. 5, pp. 663–672, May 2019, doi: 10.1093/ckj/sfz046.
[11] N. Masnoon, S. Shakib, L. Kalisch-Ellett, and G. E. Caughey, “What is polypharmacy? A systematic review of definitions,” BMC Geriatr., vol. 17, no. 1, p. 230, Oct. 2017, doi: 10.1186/s12877-017-0621-2.
[12] S Hayward, B Hole, R Denholm, P Duncan, JE Morris, SDS Fraser, RA Payne, P Roderick, NC Chesnaye, C Wanner, C Drechsler, M Postorino, G Porto, M Szymczak, M Evans, FW Dekker, KJ Jager, FJ Caskey. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the EQUAL Study. Nephrology, Dialysis and Transplantation (in press 2020)
[13] A. Secora, G. C. Alexander, S. H. Ballew, J. Coresh, and M. E. Grams, “Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults.,” Drugs Aging, vol. 35, no. 8, pp. 735–750, Aug. 2018, doi: 10.1007/s40266-018-0563-1.
[14] A. G. Society, “American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.,” J. Am. Geriatr. Soc., vol. 63, no. 11, pp. 2227–2246, Nov. 2015, doi: 10.1111/jgs.13702.
[15] P. Gallagher and D. O’Mahony, “STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria.,” Age Ageing, vol. 37, no. 6, pp. 673–679, Nov. 2008, doi: 10.1093/ageing/afn197.
[16] K. P. J. Smits et al., “Development and initial validation of prescribing quality indicators for patients with chronic kidney disease.,” Nephrol. Dial. Transplant, vol. 31, no. 11, pp. 1876–1886, Nov. 2016, doi: 10.1093/ndt/gfv420.